| Literature DB >> 35566843 |
Rachel Yie Hang Tan1, Choy Sin Lee2, Mallikarjuna Rao Pichika2,3, Sit Foon Cheng4, Ki Yan Lam1.
Abstract
Due to the specific physiological pH throughout the human body, pH-responsive polymers have been considered for aiding drug delivery systems. Depending on the surrounding pH conditions, the polymers can undergo swelling or contraction behaviors, and a degradation mechanism can release incorporated substances. Additionally, polyurethane, a highly versatile polymer, has been reported for its biocompatibility properties, in which it demonstrates good biological response and sustainability in biomedical applications. In this review, we focus on summarizing the applications of pH-responsive polyurethane in the biomedical and drug delivery fields in recent years. In recent studies, there have been great developments in pH-responsive polyurethanes used as controlled drug delivery systems for oral administration, intravaginal administration, and targeted drug delivery systems for chemotherapy treatment. Other applications such as surface biomaterials, sensors, and optical imaging probes are also discussed in this review.Entities:
Keywords: biomedical; drug delivery; pH-responsive; polyurethane
Year: 2022 PMID: 35566843 PMCID: PMC9102459 DOI: 10.3390/polym14091672
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.967
Figure 1Types of stimulus-responsive polymers.
Figure 2(A) An example of deprotonation of acidic group in a high pH medium; (B) An example of a polymer containing a carboxylic group (–COOH) with a model drug loaded. In the acidic pH medium, the pendant acidic group remains unionized and retains the drug in the polymer carrier. By increasing the pH, the pendant carboxylic group ionizes and deprotonates, and the polymer swells due to the increase of electron charge density, which induces water diffusion into the polymer network, releasing the incorporated drug.
Figure 3(A) An example of protonation of a tertiary amine group in a low pH medium; (B) An example of a polymer containing an amino group (–NH2) with a model drug loaded. In a basic pH medium, the pendant amino groups remain ionized and retain the drug within the polymer carrier. However, when the pH is decreased to become acidic, the amino groups were protonated and the polymer networks swelled due to the electrostatic repulsion between the neighboring positive groups, which induced water diffusion into the polymer network, releasing the incorporated drugs.
Figure 4(A) An example of deprotonation (at high pH) and protonation (at low pH) of an amphoteric copolymer. The carboxylic groups are labeled in purple, the amine groups labeled in green; (B) An example of a polymer containing zwitterionic ions (both carboxylic group and amino group) with model drug loaded. At the isoelectric point, the acidic pendant group, basic pendant group, cations and anions remain in equilibrium. When the pH is decreased, the amino groups are protonated, and the polymer networks swell due to the electrostatic repulsion between the neighboring positive groups, which induces water diffusion into the polymer network, releasing the incorporated drugs. When increasing the pH, the pendant carboxylic group ionized and deprotonated, and the polymer swelled due to the increase of electron charge density, which induced water diffusion into the polymer network, releasing the incorporated drug.
Figure 5Examples of cleavage of acid-labile linkages and their degradation product.
Figure 6An example of a polymer containing an acid-labile linkage with a model drug loaded. In an acidic pH environment, the acid-labile linkage hydrolyzed and bond cleavage occurred, releasing the incorporated drugs.
pH-responsive polymers categorized by the mechanism (A) Ionizable moieties and (B) Acid-labile linkages, and their application.
| Mechanism | Pendant Groups | Ionizable Group/Linkage | Responsive pH | Polymer Type | Type of Response | Application | Ref |
|---|---|---|---|---|---|---|---|
|
|
| 2-aminoethyl methacrylate | 6.5 and 6.8 | Polyplex Nanoparticles (NPs) | Improve cellular uptake and transfection efficiency | Gene Delivery | [ |
| 2-methoxy-4-aminomethyl-1,3-dioxolan | 5.5 | Poly(vinyl alcohol) | Rapid drug release | Drug carrier for tumor therapy | [ | ||
| Histidine | 5.0 | Poly(ethylene glycol)-polycaprolactone | Increase drug release | Chemotherapy | [ | ||
| 2-dimethylamino ethyl methacrylate | 4.0 and 7.0 | Poly(lactic acid) PLA | Swells and speeds drug release | Targeted drug delivery vehicles | [ | ||
| 2-dimethylamino ethyl methacrylate | 5.0 | PCL | Swells and enhances drug release | Drug delivery | [ | ||
| Chitosan | 5.5 | Poly(lactic-co-glycolic acid) | Efficient release | Tacrolimus delivery | [ | ||
| Chitosan | 5.5 | Poly(N-isopropylacrylamide)-co-itaconic acid | Fast release | Local breast cancer therapy | [ | ||
| 2-(diisopropylamino) ethyl methacrylate | 6.5 | Hydroxyethyl methacrylate-co-DPA copolymers | Increased drug release | Ocular drug delivery | [ | ||
|
| Methacrylic acid | 7.4 | Amine-modified bimodal mesopores silica | Swells and speeds drug release | Drug delivery carrier | [ | |
| Acrylic acid | 7.4 | Poly(ethylene glycol) PEG | Increased drug release | Targeted drug delivery | [ | ||
|
|
|
|
|
|
|
| |
|
| β-Thiopropionate | 5.0 | PEG | Increased drug release | Targeted cancer cell treatment | [ | |
| β-Thiopropionate | 5.0 | Poly(beta-thioether ester)-PEG | Rapid drug release | Nanocarrier for drug delivery | [ | ||
| Hydrazone linkage | 5.5 | Lipid Polymer Hybrid NPs | Fast drug release | Biomedical and chemotherapy | [ | ||
| Hydrazone linkage | 5.4 | N-isopropylacrylamide-co-glycidyl methacrylate | Increased drug release | Chemotherapy drug delivery | [ | ||
| Hydrazone linkage | 5.6 | Poly(β-benzyl malate) | Rapid drug release | Antitumor drug carrier | [ | ||
| Oxazoline | 6.0 | Poly(lactic acid)-poly(β-amino ester) | Increased drug release | Colon cancer adjuvant therapy | [ | ||
| Boron-ester linkage | 6.8 | Polymer dots | Better fluorescent intensity | Bioimaging probe | [ | ||
| Borate-ester linkage | 5.5 | PNIPAAm | Rapid drug release | Cancer therapy | [ | ||
|
| Metal ligand | 5.0 | PEG-PLGA | Rapid drug release | MRI-guided therapy | [ | |
Figure 7Structure of commonly used pendant basic groups.
Figure 8Structure of commonly used pendant acidic groups.
Figure 9The hard segment (red) and soft segment (blue) of polyurethane.
Scheme 1Conventional synthesis route of polyurethane.
Scheme 2Polyurethane synthesis via non-isocyanate routes: (A) polyaddition of bifunctional cyclic carbonate and diamine; (B) the polycondensation of ethylene carbonate, diamines and diols; (C) the cationic ring-opening polymerization of cyclic urethane; (D) the copolymerization of substituted aziridines with carbon dioxide.
Types of stimulus-responsive polyurethanes used in biomedical and drug delivery applications, and their biocompatibility and biodegradability evaluation (excluding pH-responsive).
| Type of Stimuli/Stimulus-Responsive PU | Type of Stimuli/Stimulus | * PU Type | PU Name | Reactants for Synthesis of PU | Biocompatibility Evaluation | Biodegradability Evaluation | Applications | Ref |
|---|---|---|---|---|---|---|---|---|
| Single | Thermo | A + C | Poly(ether urethane) |
Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) HDI | Ex vivo in rodent model for hydrogel injectability and gelation | ** N/A | Controlled and triggered release drug | [ |
| Redox | A + C | PU Nanoparticles |
PCL HDI |
MTS assay NP (1000 µg/mL): Lung alveolar Type 1 cells (AT1) cell viability >80% | Degrade and reach 50% weight loss (polymers with increase of disulfide bonds) in 10 mM glutathione (GSH) after 14 days | Chemotherapy drug delivery | [ | |
| Redox | A + C | PU micelles with mPEG block and PLA block with disulfide bonds |
Copolymer PLA Poly (ethylene glycol methyl ester) (MPEG) Isophorone diisocyanate (IDPI) |
CCK8 assay Blank micelles (100 mg/L): HepG2 cell viability reduced to 76.3%; HUVEC cell dropped to 65% | Decompose within 24 h in the presence of 10 mM dithiothreitol (DTT) | Anticancer drug delivery | [ | |
| Redox | A + C | PU with disulfide bonds, pendant carboxyl groups, and primary amine group |
PCL PEG HDI |
CCK8 assay Empty PU micelles (1 mg/mL): >80% cell viability for HUVEC and HepG2 cells | ** N/A | Drug delivery | [ | |
| Light | B + C | Serinol-based PU nanoparticles |
2- amino-1,3-propanediol 4,5-dimethoxy-2-nitrobenzyl (4-nitrophenyl) carbonate | ** N/A | Nanoparticle count rate decrease ~>30% after 15 min of UV irradiation | Nanocarrier for controlled drug release | [ | |
| Shape memory | N/A | Shape memory polyurethane (SMPU) | Commercial SMPU, MM3520 | ** N/A | ** N/A | Endovascular embolization | [ | |
| Dual | Shape memory + water | N/A | Thermoplastic PU/hydroxyethyl cotton cellulose nanofibers (TPU/CNF-C/CNTs) | Commercial TPU, BT-70ARYU | ** N/A | ** N/A | Sensors, actuators | [ |
| Thermo + light | A + C | PUA Nanoparticles |
PCL PLA IDPI |
VitaBright-48 (VB-48) assay, CCK8 assay NIH3T3 cell viability ~70% | Weight loss of approximately >~10% in 28 days | 3D cell-laden bioprinting | [ | |
| Thermo + shape memory | A + C | PCL-based PU |
PCL Polytetramethylene ether glycol (PTMEG) HDI |
CCK8 assay L929 fibroblast cell proliferation rate >80% | Weight loss of 67% after 13 weeks | Vascular stents | [ | |
| Thermo + enzyme | B + C | Poly(ester urethane) Nanoparticles |
1,12-dodecane diol L-tyrosine |
MTT assay WT-MEFs, HeLa, MCF7 cell viability results show non-toxic and biocompatible nature of the polymer | ** N/A | Chemotherapy drug delivery | [ | |
| Multi | Thermo + shape + water | A + C | PU/nanoporous cellulose gel (PU/NCG) |
PEG TDI | ** N/A | ** N/A | Biomaterials, sensors | [ |
* PU Type: (A) isocyanate-based PU, (B) non-isocyanate-based PU, (C) PU synthesized with petrochemical-based polyols and (D) synthesized from bio-based polyols. ** N/A: information not available.
Different types of pH-responsive PUs with their attached functional response groups and their different applications.
| Type of pH-Responsive PU | PU System | Reactants Used in Synthesis of PU | Ionizable Group/Linkage | Additional Stimulus Response | pH Responsiveness | * Applications | Reference | Reference Materials | Improvement to the Reference Materials |
|---|---|---|---|---|---|---|---|---|---|
|
| PU micelles |
PCL-Hydrazone-PEG-Hydrazone-PCL LDI | Hydrazone linkage | N/A | pH ranging from 4.0–6.0, cleavage of hydrazone bond and degraded | A | [ | N/A | N/A |
| PU micelles |
PCL PEG N-N-Dimethylacetamide (DMAc) | Hydrazone linkage | N/A | At pH 4.4, particle size increase due to swelling, drug release to 98% | A | [ | Same PU without hydrazone bond | N/A | |
| PU/DEA copolymer |
IPDI Poly(propylene glycol) diacrylate (PPGDA) | 2-(diethylamino) ethyl methacrylate | N/A | At pH 4.0, dynamic swelling and drug release | A | [ | Same PU without DEA monomers | N/A | |
| PU micelles |
PEG PCL IPDI | Diethanolamine | N/A | At pH 5.5, highest drug release | A | [ | N/A | N/A | |
| PU copolymer |
PEG 1,6-haxanediol (HD) HDI MDI | HEP | N/A | At pH 4.5, swelled twofold and close to zero drug release; however, sodium diclofenac incorporated release at elevation to pH 7.0 | A | [ | PEG-HD-MDI-HD without HEP monomers | Reversible and sharp switch between “on” and “off” drug release, serves as window membrane in reservoir-type intravaginal rings | |
| PU copolymer NPs |
MPEG IPDI |
HEP DMPA | N/A | PU containing higher HEP ratio, swelled and highest drug release at pH 5.0 | A | [ | N/A | N/A | |
| PU copolymer hydrogel |
PEG HDI PG | DMPA | N/A | Drug release at pH 7.0 | A | [ | N/A | N/A | |
| PU hydrogels- |
PVA Chitosan TDI | Poly(azomethine-urethane) (PAMU) | N/A | Highest swelling degree at pH 3.0; increase of PAMU, swelling degree increase, release of drug increase | A | [ | N/A | N/A | |
| PU nanomicelles |
PEG IPDI Poly(neopentyl glycol adipate) diol (PNA-2000) HEMA | 2-[N,N-bis (2-hydroxy-ethyl)] aminoethanesulfonic acid sodium salt (BES-Na) | N/A | Drug release rate: pH 5.0 > pH 6.8 > pH 7.4 | A | [ | N/A | N/A | |
| PU-sodium alginate (SA) blend |
Bis-hydroxyethylene terephthalate (BHET) PEG HDI | Sodium Alginate | N/A | Swelled at pH 7.4, sustained and prolonged release of incorporated protein or insulin | A | [ | N/A | BHET derived from PET waste, biocompatible | |
| Cellulose crosslinked PU |
PCL HDI |
Lactic acid (LA) Glycolic acid (GA) DMPA | N/A | All 3 PUs swelled and highest release of incorporated drugs at pH 7.4 | A | [ | N/A | Control release rate by changing chain extender; | |
| PEG-HTPB (g-COOH)-PEG triblock copolymer |
Hydroxyl-terminated polybutadiene (HTPB) MPEG HDI | Mercaptoacetic acid | N/A | At pH 7.4, micelles swelled rapidly and released drug | A | [ | N/A | N/A | |
| PU/cellulose acetate phthalate (CAP) fibers | Commercial PU | CAP | N/A | Rapid release of Rhodamine B at pH 7.4 within 1 min | A | [ | - Pure CAP | Improved tensile strength compared to previously reported CAP fibers | |
| PU films |
PEG HDI |
Lysine Arginine Glutamine | N/A | PU-Arginine shows highest drug release at pH 4.4; All PU shows average drug release of 64% at pH 10.4 | A | [ | N/A | N/A | |
| PEG-PU copolymers |
PEG HDI |
HEP DMPA | N/A | Highest pH buffering capacity 7.02, specific responsiveness not mentioned | B | [ | N/A | N/A | |
|
| PU |
PEG MDI |
DMPA MDEA | Thermo-responsive | PU-MDEA: Swells at pH 4.0–5.5 | N/A | [ | N/A | N/A |
| PU Micelles |
PCL MDI |
HEP MDEA N-butyl diethanolamine (BDEA) | Thermo-responsive | HDI-MDEA and HDI-BDEA, | A | [ | N/A | N/A | |
| PU/DPA |
PPGDA PEGMA IPDI | DPA | Thermo-responsive | Increase of DPA, results in highest swelling degree at pH 4.0 | A | [ | Same PU without addition of DPA/PPGDA/PEGMA mixture | N/A | |
| PEG-PCL based PU blend with cellulose nanocrystals (CNC) |
PEG PCL IPDI |
Pyridine-4-carbonyl chloride (-C6H4NO2) 2,2,6,6-tetramethyl-1-piperidinyloxy (-COOH) | Shape memory | CNC-COOH; At pH 4.0, folded strip of | C | [ | N/A | N/A | |
| PU |
PPG IPDI | Pyridine | Shape memory | Swells at pH 1.3, drug release and shape recovers | A, C | [ | N/A | N/A | |
| Azo-cationic waterborne polyurethane (CWPU) |
PEG PCL MDI |
MDEA Azobenzene | Photo-responsive | Shows different color in different pH medium | B | [ | N/A | N/A | |
| PU micelles with disulfide linkage |
PEG PCL LDI | MDEA | Reduction-responsive | Rapid drug release at pH 5.5 | A | [ | N/A | N/A | |
| PU with disulfide bonds |
PCL HDI Bis (2-isocyanatoethyl) disulfide (CDI) | Poly(2-ethyl-2-oxazoline)(PEOz) | Reduction-responsive | Drug release rate higher at pH 5.0 | A | [ | - End-group-carboxylated PEOz-PLA | Cumulative drug release increase with presence of 1, 4-dithio-D, L-threitol (DTT) | |
| MPEG/PU triblock copolymers with disulfide linkage |
MDI HDI MDEA BDEA | Bis-1,4-(hydroxy-ethyl) piperazine (HEP) | Reduction-responsive | pH 5.5 and 6.8, swells and faster drug release | A | [ | N/A | N/A | |
|
| PU |
PEG MDI | DMPA | Thermo-responsive and | For PEG-30%-MDI-DMPA, fixes deformed shape at pH 2.0, recovers shape at pH 9.0 | N/A | [ | N/A | N/A |
* Applications: (A) Biomedical and drug delivery, (B) optical imaging, and (C) biomaterials.
Figure 10Formation of micelle at pH 5, swelling of micelle at pH 7.4 and dissociation of carboxylic groups at pH 9 (Adapted and reprinted with permission from ref. [81] © 2016, Elsevier).
Scheme 3Protonation of amino groups in HEP when pH is decreased in an acidic medium.
Figure 11Electrospun PU acts as the membrane controlling drug release from the IVR. At pH 4.5, the PU membrane swells due to the protonation of amine groups in HEP. Due to swelling of the fiber, it blocks the pathway for the drug to be released from the IVR. When pH is increased to 7.0 (after sexual intercourse), the PU fiber shrinks and the drug is released from the IVR’s reservoir. (A) IVR; (B) window membrane; (C) reservoir (Adapted and reprinted with permission from ref. [74] © 2018, Elsevier).
Figure 12The reservoir of the IVR filled with pH-responsive dimethylolpropionic acid (DMPA)-loaded PU hydrogels, with drilled holes for diffusion of nanocarriers. The nanocarriers were observed to have higher release at pH 7.0 compared to pH 4.2, due to the deprotonation of COOH groups of the DMPA (Adapted and reprinted with permission from ref. [76] © 2018, American Chemical Society).
Scheme 4Deprotonation of carboxylic groups in dimethylolpropionic acid (DMPA) when pH is increased in a basic medium.
Figure 13Illustration of doxorubicin (DOX) drug delivery system with PU micelles containing hydrazone linkage. Inside the blood (pH 7.4), the drugs remain retain inside the lysosome. When it reaches to the tumor tissue cells (pH 5.0–6.0), the hydrazone linkage hydrolyzes and breaks the lysosome formation, hence the drug is released inside the tumor tissue cells [103,105].
Figure 14The PEGylated PU self-assembled into nanogels; the model drug, indomethacin (IND), and diselenide bonds were incorporated into the nanogels, forming a network. At lower pH environments, MDEA protonates, causing swelling and expansion of networks; at high H2O2 concentration, diselenide bonds break, causing network collapse; both result in release of IND (Adapted and reprinted with permission from ref. [108] © 2016, Elesevier).
Figure 15PEU loaded with indomethacin and Rhodamine B. At increasing pH, the nanoparticles swell, resulting in a slipping, loose network; while at increasing H2O2 concentration, the diselenide bonds break, both leading to drug release (Adapted and reprinted with permission from ref. [109] © 2016, Elesevier).
Figure 16The changes of shape of PECU/CNC-C6H4NO2 when immersed in HCl solution (pH 4.0) and NaOH solution (pH 8.0) at room temperature (Adapted and reprinted with permission from ref. [88] © 2015, American Chemical Society).